Radiotherapy & Oncology
Volume 91, Issue 1 , Pages 33-37 , April 2009

Post-mastectomy radiation in large node-negative breast tumors: Does size really matter?

  • Scott R. Floyd

      Affiliations

    • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    • Current address: Department of Radiation Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115, USA
    • ,
  • Alphonse G. Taghian

      Affiliations

    • Breast Service, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.

Received 2 December 2007 ,Revised 15 September 2008 ,Accepted 19 September 2008.

References 

  1. Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087–106.
  2. McArdle CS, Crawford D, Dykes EH, et al. Adjuvant radiotherapy and chemotherapy in breast cancer. Br J Surg. 1986;73:264–266
  3. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441–452
  4. Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996;14:1982–1992
  5. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949–955
  6. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–1648
  7. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930–42.
  8. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116–126
  9. Tennvall-Nittby L, Tengrup I, Landberg T. The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM stage II. The South Sweden Breast Cancer trial. Acta Oncol. 1993;32:641–646
  10. Velez-Garcia E, Carpenter JT, Moore M, et al. Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) trial. Eur J Cancer. 1992;28A:1833–1837
  11. Host H, Brennhovd IO, Loeb M. Postoperative radiotherapy in breast cancer–long-term results from the Oslo study. Int J Radiat Oncol Biol Phys. 1986;12:727–732
  12. Olson JE, Neuberg D, Pandya KJ, et al. The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group. Cancer. 1997;79:1138–1149
  13. Rutqvist LE, Pettersson D, Johansson H. Adjuvant radiation therapy versus surgery alone in operable breast cancer: long-term follow-up of a randomized clinical trial. Radiother Oncol. 1993;26:104–110
  14. Valagussa P, Zambetti M, Biasi S, et al. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol. 1994;5:209–216
  15. Pierce SM, Recht A, Lingos TI, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys. 1992;23:915–923
  16. Kreisman H, Wolkove N. Pulmonary toxicity of antineoplastic therapy. Semin Oncol. 1992;19:508–520
  17. Lingos TI, Recht A, Vicini F, et al. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1991;21:355–360
  18. Shapiro CL, Hardenbergh PH, Gelman R, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol. 1998;16:3493–3501
  19. Behranwala KA, Dua RS, Ross GM, et al. The influence of radiotherapy on capsule formation and aesthetic outcome after immediate breast reconstruction using biodimensional anatomical expander implants. J Plast Reconstr Aesthet Surg. 2006;59:1043–1051
  20. Soong IS, Yau TK, Ho CM, et al. Post-mastectomy radiotherapy after immediate autologous breast reconstruction in primary treatment of breast cancers. Clin Oncol (R Coll Radiol). 2004;16:283–289
  21. Wong JS, Ho AY, Kaelin CM, et al. Incidence of major corrective surgery after post-mastectomy breast reconstruction and radiation therapy. Breast J. 2008;14:49–54
  22. Taghian AG, Jeong JH, Mamounas EP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006;24:3927–3932
  23. Floyd SR, Buchholz TA, Haffty BG, et al. Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5cm and larger. Int J Radiat Oncol Biol Phys. 2006;66:358–364
  24. Helinto M, Blomqvist C, Heikkila P, et al. Post-mastectomy radiotherapy in pT3N0M0 breast cancer: is it needed?. Radiother Oncol. 1999;52:213–217
  25. Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000;18:2817–2827
  26. Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol. 2003;21:1205–1213
  27. Trudeau ME, Pritchard KI, Chapman JA, et al. Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Res Treat. 2005;89:35–45
  28. Ragaz J, Spinelli JJ. Large breast cancer tumors and radiotherapy: biology vs chronology. Radiother Oncol. 1999;52:203–205
  29. Klefstrom P, Grohn P, Heinonen E, et al. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. II. 5-year results and influence of levamisole. Cancer. 1987;60:936–942
  30. Fracchia AA, Evans JF, Eisenberg BL. Stage III carcinoma of the breast. A detailed analysis. Ann Surg. 1980;192:705–710
  31. Buchholz TA, Hunt KK, Whitman GJ, et al. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer. 2003;98:1150–1160
  32. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer v.1.2008, available from: www.nccn.org.
  33. Truong PT, Olivotto IA, Whelan TJ, et al. Clinical practice guidelines for the care and treatment of breast cancer: 16 locoregional post-mastectomy radiotherapy. CMAJ. 2004;170:1263–1273
  34. Recht A, Bartelink H, Fourquet A, et al. Postmastectomy radiotherapy: questions for the twenty-first century. J Clin Oncol. 1998;16:2886–2889
  35. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539–1569
  36. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst. 2001;93:979–989
  37. Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol. 1999;17:1689–1700
  38. Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004;22:4247–4254
  39. Nielsen HM, Overgaard M, Grau C, et al. Loco-regional recurrence after mastectomy in high-risk breast cancer--risk and prognosis. An analysis of patients from the DBCG 82b&c randomization trials. Radiother Oncol. 2006;79:147–155
  40. Katz A, Strom EA, Buchholz TA, et al. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys. 2001;50:735–742
  41. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–187
  42. Ravdin PM, De Laurentiis M, Vendely T, et al. Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst. 1994;86:1771–1775
  43. Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer. 1997;79:1918–1922
  44. Chadha M, Chabon AB, Friedmann P, et al. Predictors of axillary lymph node metastases in patients with T1 breast cancer. A multivariate analysis. Cancer. 1994;73:350–353
  45. Beenken SW, Urist MM, Zhang Y, et al. Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg. 2003;237:732–738[discussion 738–739]
  46. Jagsi R, Abi Raad R, Goldberg S, et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: Implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2005;[available Online, March 19, 2005]
  47. Mignano JE, Gage I, Piantadosi S, et al. Local recurrence after mastectomy in patients with T3pN0 breast carcinoma treated without postoperative radiation therapy. Am J Clin Oncol. 2007;30:466–472
  48. Yu JB, Wilson LD, Dasgupta T, et al. Postmastectomy radiation therapy for lymph node-negative, locally advanced breast cancer after modified radical mastectomy: analysis of the NCI surveillance, epidemiology, and end results database. Cancer. 2008;113:38–47
  49. McCammon R, Finlayson C, Schwer A, et al. Impact of postmastectomy radiotherapy in T3N0 invasive carcinoma of the breast: a surveillance, epidemiology, and end results database analysis. Cancer. 2008;113:683–689
  50. Ceilley E, Jagsi R, Goldberg S, et al. Radiotherapy for invasive breast cancer in North America and Europe: results of a survey. Int J Radiat Oncol Biol Phys. 2005;61:365–373
  51. Cheng SH, Horng CF, West M, et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol. 2006;24:4594–4602
  52. Nuyten DS, Kreike B, Hart AA, et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res. 2006;8:R62

PII: S0167-8140(08)00517-3

doi: 10.1016/j.radonc.2008.09.015

Radiotherapy & Oncology
Volume 91, Issue 1 , Pages 33-37 , April 2009

Article Tools